OSSIO Secures $27.6M to Scale Bio-Integrative Implant Technology in Orthopedic Surgery

OSSIO, a medical device company that aims to revolutionize orthopedic surgery. It has recently gained $27.6 million in equity funding for acceleration. This investment will assist the company in scaling commercial operations by developing new products, increasing sales channels, advancing medical education, and building its manufacturing facility and surgeon training center in Florida. OSSIOfiber implants, OSSIO’s flagship product, provides an unprecedented solution for orthopedic fixation: strong and temporary fixation that is absorbed by the body and replaced with natural bone.

Bio-Integrative Technology

OSSIOfiber is at the heart of OSSIO’s technology. It is a proprietary bio-integrative fixation material that provides the strength required for orthopedic procedures while avoiding the risks associated with traditional metal implants. OSSIOfiber implants, unlike traditional metals, do not retain any permanent materials in the body. Instead, after carrying out their function of fixation, the implants naturally integrate into the bone and are replaced by the patient’s own tissue, reducing the chances of post-surgical complications and the need for secondary procedures.

This innovative technology addresses an old problem in orthopedic surgery: the need for a long-lasting fixation material that will not cause biological complications for an extended period of time and should not be removed following the surgical procedure. The OSSIO implants are based on a polymeric mineral fiber matrix, promoting bone regeneration and in-growth, with safer and more natural alternatives as opposed to metal and absorbable implants.

Commercial Expansion

Questa Capital, a growth equity firm focused on healthcare investments, led the Series funding round, which also saw participation from MVM Partners, OCV, Ortho-Vision, and Courage Capital. According to OSSIO’s CEO, Brian Verrier, the new investment will allow the company to enhance its commercial footprint and drive broader adoption of OSSIOfiber implants across both U.S. and international markets. The funds will also be used to expand OSSIO’s sales team, increase support for distribution partners, and ramp up manufacturing capacity in anticipation of future growth.

We’re investing in new product innovation, sales growth, and increased manufacturing capability to address the demand and serve our growing footprint in the approximately $16 billion orthopedic fixation market,” said Verrier. “With this fund, we will be able to further pursue our vision in transforming the practice of orthopedic surgery by offering the first true innovation beyond metal for implants.”

A Growing Leader

Since its first product in 2019, OSSIO has really made big leaps in the orthopedic marketplace. Over 50,000 OSSIOfiber implants have been utilized in various procedures in orthopedics. Because of its evident patient benefit–reduction of complications linked with metal implants, plus strong surgeon preference for this biologically integrated solution–its novel technology is gaining steam.

The company’s success is in line with the investment approach of Ryan Drant, Founder and Managing Partner of Questa Capital, who emphasized the value of OSSIO’s differentiated technology in the market. “OSSIO fits squarely into our investment strategy,” said Drant. “We are excited to support a company that is rapidly growing and has demonstrated both strong demand and surgeon adoption for its unique implant technology.”

A Vision for the Future

With the new funding, OSSIO is well-positioned to accelerate its growth and innovation in the orthopedic space. The company’s long-term goal is to continue expanding the clinical applications of its OSSIOfiber implants across a wide range of orthopedic procedures, aiming to become the preferred fixation device in the field. By using no permanent materials and allowing for a more significant strength of fixation that interlocks with the bone, OSSIO hopes to change the paradigm of orthopedic surgery.

In addition to enlarging its product portfolio, OSSIO will continue educational programs designed to help surgeons and other medical professionals. To further advance the field of orthopedic surgery, the company will open a surgeon training center in Florida to facilitate hands-on, direct exposure and product adoption.

Meeting Market Needs

The orthopedic fixation market is valued at over $16 billion and has increasing demand for alternatives to traditional metal implants. OSSIO’s bio-integrative technology is very appealing to healthcare providers and payors in the U.S. because it utilizes existing reimbursement codes and surgical techniques. The ability to integrate with existing surgical workflows has been a key factor in the rapid adoption of OSSIOfiber implants.

The implants have several advantages over metal-based alternatives, such as fewer complications, fewer secondary procedures, and better recovery for the patient. OSSIO’s solution is becoming a preferred choice for both surgeons and patients who seek to avoid the long-term risks associated with metal fixation devices.

Growth Strategy and Market Expansion

With the $27.6 million in funding, OSSIO plans to further expand its presence in the U.S. and international markets. The company aims to strengthen its partnerships with distributors and increase adoption among hospitals and surgery centers worldwide. Additionally, the company is focused on increasing manufacturing capacity to meet the growing demand for its innovative implants.

The company is positioning itself to be a leader in the orthopedic fixation space by continuing to develop its product portfolio and expand its commercial footprint. The company is committed to advancing the practice of orthopedic surgery by offering a safer, more effective alternative to traditional fixation methods.

About OSSIO and OSSIOfiber Implants

OSSIO is a medical device company established in 2014 and dedicated to transforming orthopedic surgery with its Intelligent Bone Regeneration Technology. OSSIOfiber is its flagship product, a material that can provide the strength of orthopedic procedures while still integrating naturally into the bone. It provides a biologically safe alternative to metal implants. OSSIO will be committed to advancing orthopedic surgery by developing innovative products that improve patient outcomes and streamline surgical procedures.

With its offices both in Caesarea, Israel, and Woburn, Massachusetts, OSSIO is rapidly increasing its global market presence. Long term the company aims to transform orthopedic fixation by providing safer and more effective alternatives over metal and absorbable implants.

source: Businesswire